ClinicalTrials.gg
CompletedNCT00129220Updated Dec 28, 2010Results posted

Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

A Phase 3 interventional study of olanzapine and haloperidol in Bipolar Disorder, sponsored by Eli Lilly and Company. Completed at 16 sites in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-12-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.

Enrollment
6th of 28
224 · median 120
Started
2005
with 3 others
Phase 3
7 of 28
none open now
Registered
6th of 28
by date
Lead sponsor
13 of 28
Eli Lilly and Company

Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 6th largest by enrollment, is one of 4 that started in 2005, is one of 7 in phase 3, and was the 6th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing olanzapine in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • Manic or mixed episode associated with bipolar I disorder
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the criteria for manic or mixed episodes according to the Fourth Edition, Text Revision (DSM-IV-TR) and have a diagnosis of "294.4x Bipolar I Disorder, Most Recent Episode Manic" or "296.6x Bipolar I Disorder, Most Recent Episode Mixed".
  • Have a total score on the Young Mania Rating Scale (YMRS) of at least 20 at Visit 1 and Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Have received an antidepressant or a psychostimulant within 5 days prior to Visit 1.
  • The duration of the current episode is more than 90 days at Visit 1.
  • Have a history or a diagnosis of diabetes mellitus.
  • Have received any psychotropic medication within 2 days prior to Visit 2 (except for benzodiazepines).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Olanzapine

    olanzapine: 5 to 20 mg per day for 6 weeks

    Drug: olanzapine

  • Active comparator
    Haloperidol

    haloperidol: 2.5 to 10 mg per day for 6 weeks

    Drug: haloperidol

  • Placebo comparator
    Placebo

    placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks

    Drug: placebo

Interventions

  • 5-20 mg, oral, once daily (evening), for 6 weeks

    Also known as: LY170053, Zyprexa

  • 2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.

  • Drugplacebo

    placebo, oral tablets, twice daily (morning and evening), for 3 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline, 3 weeks

Secondary outcomes

  1. Change From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS)

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline, 6 weeks

  2. Remission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol)

    Remission of bipolar disorder was defined as completing the 6-week period with meeting the criteria for Young Mania Rating Scale (YMRS) total score of 12 or less and 17-Item Hamilton Depression Rating Scale (HAMD-17) total scores of 7 or less at Week 6. YMRS is an 11-item scale measuring severity of manic episodes; total score ranges = 0 (normal) to 60 (severe). The 17-item HAMD measures depression severity; total score ranges = 0 (normal) to 52 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.

    Time frame: 6 weeks

  3. Change From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness

    A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of overall mood symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline, 6 weeks

  4. Change From Baseline to 3 Week and 6 Week Endpoints in Clinical Global Impression - Bipolar Version (CGI-BP) Mania Subscale

    A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of manic symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline, 3 weeks, 6 weeks

  5. Response Rate of Manic Symptoms at 3 Weeks and 6 Weeks

    Participants who had 50 percent or more decrease from the baseline in YMRS total scores were defined as a responder. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. Response Rate (percent) = number of patients meeting response criterion for manic symptom divided by number of patients in treatment arm, multiplied by 100.

    Time frame: Baseline, 3 weeks, 6 weeks

  6. Remission Rate of Manic Symptoms at 3 Weeks and 6 Weeks

    Participants who had a YMRS total score of 12 or less were considered to be in remission of manic symptoms. YMRS is an 11-item scale that measures severity of manic episodes; total score ranges from 0 (normal) to 60 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.

    Time frame: 3 weeks, 6 weeks

  7. Percentage of Participants Who Switched to Symptomatic Depression

    Switch to symptomatic depression was defined as HAMD-17 total score ≥13 at any time in the participants with HAMD-17 total scores ≤7 at baseline. The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

    Time frame: 3 weeks, 6 weeks

  8. Change From Baseline to 3 Week and 6 Week Endpoints in the Positive Subscore of Positive and Negative Syndrome Scale (PANSS)

    Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale (ex. delusions, conceptual disorganization, and hallucinatory behavior). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For this study, the score was converted to 0 to 6 for each item range; hence, the total positive subscale score ranges from 0 to 42.

    Time frame: Baseline, 3 weeks, 6 weeks

  9. Percentage of Participants Who Switched to Syndromic Depression

    Switch to syndromic depression was operationally defined by meeting both of the following criteria: At baseline, the symptoms did not meet the criteria for a mixed episode based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR). The critiera were met for a Major Depressive Episode (MDE), at any point after randomization, based on DSM-IV-TR. Rather than the 2-week period required for an MDE in the DSM-IV-TR, the patient had to meet the criteria of an MDE for at least 7 consecutive days (during Weeks 1 through 6).

    Time frame: 3 weeks, 6 weeks

  10. Maximum Change From Baseline During 6-Week Period in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score

    Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe).

    Time frame: Baseline to 6 weeks

07

Results

Posted Feb 15, 2010
Limitations and caveats
Identified errors were corrected.

Participant flow

Study Period II
Participant flow — Study Period II
MilestoneOlanzapineHaloperidolPlacebo
Started1052099
Received at least one dose of study drug1042097
Completed72852
Not completed331247
Withdrew: Adverse event957
Withdrew: Lack of efficacy15128
Withdrew: Entry criteria not met202
Withdrew: Protocol violation421
Withdrew: Physician decision010
Withdrew: Withdrawal by subject134
Withdrew: Reason not specified205
Study Period III
Participant flow — Study Period III
MilestoneOlanzapineHaloperidolPlacebo
Started72852
Completed59742
Not completed13110
Withdrew: Adverse event103
Withdrew: Protocol violation112
Withdrew: Withdrawal by subject103
Withdrew: Sponsor decision100
Withdrew: Reason not specified902

Outcome measures

PrimaryChange From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline, 3 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score
units on a scaleOlanzapineHaloperidolPlacebo
Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score-12.6 ± 10.0-14.3 ± 11.4-6.8 ± 14.0
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -5.62 · 95% CI -8.87 to -2.37Least Squares Mean Difference = Olanzapine minus Placebo.
SecondaryChange From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS)

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline, 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS)
units on a scaleOlanzapineHaloperidolPlacebo
Change From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS)-16.0 ± 11.4-14.7 ± 13.1-10.1 ± 15.8
Statistical analysis
  • Olanzapine vs Haloperidol · ANCOVA · p = 0.774 · Least squares mean difference: -0.78 · 95% CI -6.15 to 4.59Least Squares Mean Difference = Olazapine minus Haloperidol.
SecondaryRemission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol)

Remission of bipolar disorder was defined as completing the 6-week period with meeting the criteria for Young Mania Rating Scale (YMRS) total score of 12 or less and 17-Item Hamilton Depression Rating Scale (HAMD-17) total scores of 7 or less at Week 6. YMRS is an 11-item scale measuring severity of manic episodes; total score ranges = 0 (normal) to 60 (severe). The 17-item HAMD measures depression severity; total score ranges = 0 (normal) to 52 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.

Time frame:
6 weeks
Reported as:
Number · percentage of participants
Remission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol)
percentage of participantsOlanzapineHaloperidol
Remission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol)44.220.0
Statistical analysis
  • Olanzapine vs Haloperidol · Cochran-Mantel-Haenszel · p = 0.064 · Least squares mean difference: 21.0 · 95% CI 1.6 to 40.4Least Squares Mean Difference = Olanzapine minus Haloperidol.
SecondaryChange From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness

A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of overall mood symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline, 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness
units on a scaleOlanzapineHaloperidolPlacebo
Change From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness-1.6 ± 1.5-1.3 ± 1.8-0.9 ± 1.7
Statistical analysis
  • Olanzapine vs Haloperidol · ANCOVA · p = 0.171 · Least squares mean difference: -0.47 · 95% CI -1.15 to 0.21Least Squares Mean Difference = Olanzapine minus Haloperidol.
SecondaryChange From Baseline to 3 Week and 6 Week Endpoints in Clinical Global Impression - Bipolar Version (CGI-BP) Mania Subscale

A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of manic symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline, 3 weeks, 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 3 Week and 6 Week Endpoints in Clinical Global Impression - Bipolar Version (CGI-BP) Mania Subscale
units on a scaleOlanzapineHaloperidolPlacebo
3-Week Change-1.2 ± 1.2-1.7 ± 1.7-0.6 ± 1.5
6-Week Change-1.7 ± 1.5-1.9 ± 1.9-1.0 ± 1.7
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.006 (P-value for 3-Week Change.) · Least squares mean difference: -0.51 · 95% CI -0.87 to -0.15Least Squares Mean Difference = Olanzapine minus Placebo.
  • Olanzapine vs Haloperidol · ANCOVA · p = 0.722 (P-value for 6-Week Change.) · Least squares mean difference: -0.13 · 95% CI -0.82 to 0.57Least Squares Mean Difference = Olanzapine minus Haloperidol.
SecondaryResponse Rate of Manic Symptoms at 3 Weeks and 6 Weeks

Participants who had 50 percent or more decrease from the baseline in YMRS total scores were defined as a responder. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. Response Rate (percent) = number of patients meeting response criterion for manic symptom divided by number of patients in treatment arm, multiplied by 100.

Time frame:
Baseline, 3 weeks, 6 weeks
Reported as:
Number · percentage of participants
Response Rate of Manic Symptoms at 3 Weeks and 6 Weeks
percentage of participantsOlanzapineHaloperidolPlacebo
3 Week Response Rate51.065.044.3
6 Week Response Rate67.365.055.7
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.333 (P-value for 3-Week Response Rate.) · Mean difference (net): 6.7 · 95% CI -6.7 to 20.1
  • Olanzapine vs Haloperidol · Cochran-Mantel-Haenszel · p = 0.908 (P-value for 6-Week Response Rate.) · Mean difference (net): -1.3 · 95% CI -21.0 to 18.4
SecondaryRemission Rate of Manic Symptoms at 3 Weeks and 6 Weeks

Participants who had a YMRS total score of 12 or less were considered to be in remission of manic symptoms. YMRS is an 11-item scale that measures severity of manic episodes; total score ranges from 0 (normal) to 60 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.

Time frame:
3 weeks, 6 weeks
Reported as:
Number · percentage of participants
Remission Rate of Manic Symptoms at 3 Weeks and 6 Weeks
percentage of participantsOlanzapineHaloperidolPlacebo
3-Week Remission Rate47.165.041.2
6-Week Remission Rate63.560.052.6
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.384 (P-value for 3-Week Remission Rate.) · Least squares mean difference: 5.9 · 95% CI -7.3 to 19.2Least Squares Mean Difference = Olanzapine minus Placebo.
  • Olanzapine vs Haloperidol · Cochran-Mantel-Haenszel · p = 0.982 (P-value is for 6-Week Remission Rate) · Least squares mean difference: 0.3 · 95% CI -21.3 to 21.8Least Squares Mean Difference = Olanzapine minus Haloperidol.
SecondaryPercentage of Participants Who Switched to Symptomatic Depression

Switch to symptomatic depression was defined as HAMD-17 total score ≥13 at any time in the participants with HAMD-17 total scores ≤7 at baseline. The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

Time frame:
3 weeks, 6 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Switched to Symptomatic Depression
percentage of participantsOlanzapineHaloperidolPlacebo
3-Week Symptomatic Depression Rate2.416.71.3
6-Week Symptomatic Depression Rate2.416.72.7
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.698 (P-value for 3-Week Symptomatic Depression Rate.) · Mean difference (net): 0.8 · 95% CI -3.2 to 4.9
  • Olanzapine vs Haloperidol · Cochran-Mantel-Haenszel · p = 0.014 (P-value for 6-Week Symptomatic Depression Rate.) · Mean difference (net): -14.1 · 95% CI -31.7 to 3.4
SecondaryChange From Baseline to 3 Week and 6 Week Endpoints in the Positive Subscore of Positive and Negative Syndrome Scale (PANSS)

Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale (ex. delusions, conceptual disorganization, and hallucinatory behavior). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For this study, the score was converted to 0 to 6 for each item range; hence, the total positive subscale score ranges from 0 to 42.

Time frame:
Baseline, 3 weeks, 6 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 3 Week and 6 Week Endpoints in the Positive Subscore of Positive and Negative Syndrome Scale (PANSS)
units on a scaleOlanzapineHaloperidolPlacebo
3-Week Change-1.8 ± 4.1-1.8 ± 4.3-0.0 ± 5.3
6-Week Change-2.2 ± 4.4-1.6 ± 4.3-0.3 ± 5.7
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.019 (P-value for 3-Week Change.) · Least squares mean difference: -1.48 · 95% CI -2.71 to -0.25Least Squares Mean Difference = Olanzapine minus Placebo.
  • Olanzapine vs Haloperidol · ANCOVA · p = 0.855 (P-value for 6-Week Change.) · Least squares mean difference: -0.16 · 95% CI -1.95 to 1.62Least Squares Mean Difference = Olanzapine minus Haloperidol.
SecondaryPercentage of Participants Who Switched to Syndromic Depression

Switch to syndromic depression was operationally defined by meeting both of the following criteria: At baseline, the symptoms did not meet the criteria for a mixed episode based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR). The critiera were met for a Major Depressive Episode (MDE), at any point after randomization, based on DSM-IV-TR. Rather than the 2-week period required for an MDE in the DSM-IV-TR, the patient had to meet the criteria of an MDE for at least 7 consecutive days (during Weeks 1 through 6).

Time frame:
3 weeks, 6 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Switched to Syndromic Depression
percentage of participantsOlanzapineHaloperidolPlacebo
3-Week Syndromic Depression Rate0.05.30.0
6-Week Syndromic Depression Rate1.15.30.0
Statistical analysis
  • Olanzapine vs Haloperidol · Cochran-Mantel-Haenszel · p = 0.136 (P-value for 6-Week Syndromic Depression Rate.) · Mean difference (net): -4.6 · 95% CI -14.9 to 5.7
SecondaryMaximum Change From Baseline During 6-Week Period in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score

Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe).

Time frame:
Baseline to 6 weeks
Reported as:
Mean · units on a scale
Maximum Change From Baseline During 6-Week Period in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score
units on a scaleOlanzapineHaloperidolPlacebo
Baseline0.20 ± 0.660.50 ± 1.190.30 ± 0.91
Maximum Change from Baseline0.70 ± 1.512.70 ± 2.890.09 ± 1.09
Statistical analysis
  • Olanzapine vs Haloperidol · Wilcoxon Rank Sum · p = 0.003 (P-value for Maximum Change from Baseline.)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olanzapine—1/105 (1%)78/105 (74.3%)
Haloperidol—0/20 (0%)14/20 (70%)
Placebo—3/96 (3.1%)64/96 (66.7%)
Most frequent serious events
Most frequent serious events
EventOlanzapineHaloperidolPlacebo
Status epilepticusNervous system disorders0/1050/201/96
Bipolar I disorderPsychiatric disorders1/1050/201/96
ManiaPsychiatric disorders0/1050/201/96
Most frequent other events
Showing 10 of 37
Most frequent other events
EventOlanzapineHaloperidolPlacebo
SomnolenceNervous system disorders25/1053/2015/96
ThirstGeneral disorders16/1051/202/96
AkathisiaNervous system disorders3/1053/200/96
DystoniaNervous system disorders0/1053/201/96
ConstipationGastrointestinal disorders10/1052/203/96
MalaiseGeneral disorders6/1052/204/96
NasopharyngitisInfections and infestations9/1052/209/96
TremorNervous system disorders3/1052/201/96
Weight increasedInvestigations10/1051/204/96
Increased appetiteMetabolism and nutrition disorders7/1051/204/96

Baseline characteristics

Age Continuous
Age Continuous(years)OlanzapineHaloperidolPlaceboTotal
Mean43.1 ± 12.049.3 ± 11.942.5 ± 10.943.4 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)OlanzapineHaloperidolPlaceboTotal
Female55957121
Male491140100
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)OlanzapineHaloperidolPlaceboTotal
Japanese1042097221
Region of Enrollment
Region of Enrollment(participants)OlanzapineHaloperidolPlaceboTotal
Japan1042097221
Current Illness Episode: Manic versus Mixed
Current Illness Episode: Manic versus Mixed(participants)OlanzapineHaloperidolPlaceboTotal
Manic951989203
Mixed91818
Current Illness Episode: Psychotic versus Nonpsychotic
Current Illness Episode: Psychotic versus Nonpsychotic(participants)OlanzapineHaloperidolPlaceboTotal
Psychotic1741940
Nonpsychotic871678181
Hospitalization Status
Hospitalization Status(participants)OlanzapineHaloperidolPlaceboTotal
In-Patients41103889
Out-Patients631059132
Psychosis
Psychosis(participants)OlanzapineHaloperidolPlaceboTotal
Mood-Congruent1641939
Mood-Incongruent1001

8 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 470-1168, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Akita, 010-1654, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 283-0062, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 807-8555, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gunma, 370-2455, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 004-0841, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 663-8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 236-0037, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 861-0002, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagano, 384-8540, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 700-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okinawa, 904-2222, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 561-0803, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saga, 842-0192, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 343-0032, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 160-0023, Japan
09

References and documents

Publications

  • Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord. 2012 Feb;136(3):476-84. doi: 10.1016/j.jad.2011.10.045. Epub 2011 Nov 30. PubMed 22134043 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2005
First posted
Aug 11, 2005
Start
Jul 2005
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Feb 15, 2010
Last update
Dec 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00129220
First posted
Aug 11, 2005
Start date
Jul 2005
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Feb 15, 2010
Last update
Dec 28, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Monday-Friday 9am-5pm Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion